Vertex Rises After FDA Staff Finds Hepatitis Drug Effective
This article is for subscribers only.
Vertex Pharmaceuticals Inc. jumped 10 percent in Nasdaq stock market trading after U.S. regulators said the company’s experimental hepatitis C drug cures more patients than current therapies.
Telaprevir, combined with standard treatments, was more effective than those drugs alone in clinical trials, Food and Drug Administration staff said today in a preliminary review on the agency’s website. Outside advisers to the FDA are scheduled to meet April 28 to weigh the drug’s benefits and risks.